Cultural Variation in Symptom Expression and Illness Labeling
ME/CFS is diagnosed using Western clinical criteria. But what if the same underlying condition is called by a different name, expressed through different symptoms, and legitimized through different cultural frameworks in different parts of the world?
Ware and Kleinman’s landmark 1992 cross-cultural comparison documented that neurasthenia in China and CFS in the United States were different cultural idioms for overlapping syndromes of profound fatigue and somatic distress (Ware1992cultureSomatic?). In Chinese medical culture, patients expressed distress through somatic symptoms — headache, dizziness, weakness, fatigue — not as a psychological deficit but as a culturally legitimate form of illness expression. Lee’s ethnographic work in Hong Kong and mainland China demonstrated that shenjing shuairuo (neurasthenia) persisted as the culturally acceptable idiom for fatigue and distress well into the 2000s, serving the same social function that CFS/ME serves in Western contexts (Lee1998neurastheniaChina?). Starcevic mapped the conceptual relationship between neurasthenia and CFS, noting that global diagnostic expansion partially displaces neurasthenia in urban/professional populations while it persists in other communities (Starcevic1999neurasthenia?).
(Certainty: 0.40 — the cultural-idiom literature is conceptually rich but empirically limited: small qualitative samples, China/US focus, predating modern ME/CFS criteria. The core finding — that illness labeling is culturally moderated — is well-replicated across medical anthropology. The inference — that applying Western criteria in non-Western settings produces artifactually low prevalence — is logically sound but untested.)
Consequence: When researchers apply Fukuda or IOM criteria in a community where fatigue is expressed as “weakness” or “brain fog” has no direct translation, they count fewer cases than exist. The global prevalence map of ME/CFS is as much a map of diagnostic-criteria portability as it is a map of disease distribution. Severity applicability: all — cultural framing affects symptom reporting across all severity levels.
Falsifiable prediction: If a culturally adapted IOM screening instrument (cognitive-interview-validated in the target language) and a directly translated standard IOM instrument produce statistically equivalent PEM prevalence (p > 0.05, non-inferiority margin 5%) in the same community sample, cultural-idiom confounding is negligible for case ascertainment — direct translation is sufficient.
The neurasthenia/CFS literature covers China, Hong Kong, and to a lesser extent Eastern Europe. It does not cover South Asia (India, Pakistan, Bangladesh), Sub-Saharan Africa, Latin America, or the Middle East. In India, for instance, chronic fatigue may present through Ayurvedic frameworks (vata imbalance) or through somatic idioms of “weakness” (kamzori) that never reach a Western diagnostician. In Sub-Saharan Africa, chronic fatigue may be attributed to malaria, HIV, or “thinking too much” — culturally specific idioms that map poorly onto ME/CFS case definitions. These are research gaps, not evidence of absence.
(Certainty: 0.20 — zero empirical cross-cultural ME/CFS studies from South Asia, Africa, or Latin America. Inference drawn from medical anthropology of other chronic conditions.)
Consequence: A Zimbabwean woman with post-HIV chronic fatigue, PEM, and cognitive impairment will not be diagnosed with ME/CFS — not because she does not have it, but because neither her healthcare system nor her cultural illness framework has the category. Until culturally validated ME/CFS screening tools exist for non-Western settings, prevalence estimates are artifactually bounded to high-income countries. Severity applicability: unknown.